Now, he is practicing his faith in a different line of work: Kahn runs a dispensary for medical marijuana. Call it a mitzvah — or one of God’s commandments. “From the Jewish perspective, nothing is more important than the concept of healing and bringing sufferers relief,” said Kahn, 61. “I was a congregational rabbi during the worst days of the AIDS epidemic and saw up-close and personal what people living with AIDS were dealing with and finding relief with medical marijuana,” he said. Just last month, Kahn and his wife, who works as a nurse at a long-term acute care hospital, opened the Takoma Wellness Center on the outskirts of Washington, D.C., where they are legally allowed to dispense medical marijuana. So far, they only have three customers, who must meet state criteria and suffer from one of five diseases: HIV, AIDS, cancer, multiple sclerosis or glaucoma. “The cannabis plant was created by God on the second day of creation when God created all the other plants, and touching this one isn’t forbidden,” Kahn said in a June interview with New Voices , a national magazine for Jewish college students. Stephanie Reifkind Kahn, 59, has decorated the dispensary with “hamsas,” a Jewish and Arabic symbol to ward off evil. “They are Middle Eastern for healing and protection,” she said. “It’s something the Arab and Israeli communities agree upon. It is our shared connection.” The Kahns are able to offer their for-profit services under the district’s Medical Marijuana Program that launched Aug. 1. All proceeds will go to HIV/AIDS charities, according to the Kahns. Rabbi Kahn comes from the liberal stream of the Jewish faith, but he is not alone in his support of medical marijuana. The Jewish Advocate just recently reported that the regional co-director of the Chabad of Eastern Massachusetts , which is part of the orthodox stream, had applied for a medical marijuana dispensary license , one of 181 in that state. The rabbi, Chaim Prus of the Beth Menachem Chabad of Newton, told ABCNews.com that he would be unable to comment until the licensing process is complete.
Medical Call Center Provider, AnswerNow, Announces Compliance to Upcoming HIPAA HI-TECH Act Mandates
See also delay times for other exchanges . Quotes and other information supplied by independent providers identified on the Yahoo! Finance partner page . Quotes are updated automatically, but will be turned off after 25 minutes of inactivity. Quotes are delayed at least 15 minutes. All information provided “as is” for informational purposes only, not intended for trading purposes or advice. Neither Yahoo! nor any of independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. By accessing the Yahoo! site, you agree not to redistribute the information found therein. Fundamental company data provided by Capital IQ . Historical chart data and daily updates provided by Commodity Systems, Inc.
MiMedx® Adds Vice President of Medical Affairs
Fetterolf is an expert in the design, evaluation, reporting and analytics of clinical studies, and his expert focus on these matters will benefit us later in 2014 and 2015,” added Bill Taylor, President and COO. In addition to Dr. Fetterolf and Dr. Stanziano, the MiMedx team of Medical Directors consists of Dr. Christopher Clare, who serves as the Company’s Consulting Medical Director for Neuroscience, and Dr. Paul Davis, III, who serves as the Company’s Consulting Medical Director for Orthopedics. “MiMedx is fortunate to have an accomplished team of Medical Directors with in-depth experience in a wide-range of medical disciplines. Dr. Clare and Dr. Davis provide medical consultation and clinical study advice in their respective specialties, and are vital contributors to these two growth areas for the Company’s products,” commented Petit. “Each of our Consulting Medical Directors is well respected in his medical field of specialty, and together they provide MiMedx with insight and perspectives relating to two very important medical areas where our dehydrated human amnion/chorion membrane (dHACM) allografts can provide improved clinical and economic outcomes.” The contemplated clinical studies will support future reimbursement initiatives for our Section 361 allografts serving these specialties,” said Taylor. “Also, as we have stated for over a year, we expect that some future tissue products may be regulated outside of the Section 361 regulatory pathway. These products may need approval via the FDA’s Biologics License Applications (BLA) process, which also would require clinical studies.” Dr. Clare is a recognized thought leader and former practicing physician in the field of neurosurgery and the treatment of spinal injuries. He brings a comprehensive understanding of healthcare issues from the perspective of the practitioner, administrator and executive.